Eli Lilly & Co. vs Moderna, Inc.
LLY vs MRNA — side-by-side comparison from reported financials. LLY leads 7, MRNA leads 4 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Moderna, Inc.
MRNA · Healthcare
$225.15+14.29%Strong
| Metric | LLY | MRNA |
|---|---|---|
| Price | $1 177.20 | $225.15 |
| Market cap | $1.05T | $89.9B |
| Revenue (TTM) | $79.7B | $2.23B |
| Revenue growth | +31.7% | -53.4% |
| Net margin | 33.5% | -141.4% |
| Free cash flow | $18.2B | -$1.24B |
| Net cash (debt) | ($35.2B) | $5.21B |
| 1-year price return | +37.6% | +717.8% |
| P/E | 41.6 | 3.9 |
| P/E vs own history (cheap-side %) | 88% | 10% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | -39% |
| Altman Z-score | 7.10 | 13.40 |
| CV checks passed | 11 of 11 | 6 of 11 |
| Employees | 50,000 | 4,700 |
Full résumé-style profiles: LLY CV · MRNA CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.